Evaluation of controlled attenuation parameter in assessing hepatic steatosis in patients with autoimmune liver diseases.
Evaluation of controlled attenuation parameter in assessing hepatic steatosis in patients with autoimmune liver diseases.
复制标题
受控衰减参数评估自身免疫性肝病患者肝脂肪变性的评价。
DOI：
10.3748/wjg.v27.i1.80
复制
发表时间：
2021-01-07
影响因子：
4.3
通讯作者：
Hua J
中科院分区：
文献类型：
--
作者：
Ni XX;Lian M;Wu HM;Li XY;Sheng L;Bao H;Miao Q;Xiao X;Guo CJ;Li H;Ma X;Hua J
Hepatic steatosis commonly occurs in some chronic liver diseases and may affect disease progression. To investigate the performance of controlled attenuation parameter (CAP) for the diagnosis of hepatic steatosis in patients with autoimmune liver diseases (AILDs). Patients who were suspected of having AILDs and underwent liver biopsy were consistently enrolled. Liver stiffness measurement (LSM) and CAP were performed by transient elastography. The area under the receiver operating characteristic (AUROC) curve was used to evaluate the performance of CAP for diagnosing hepatic steatosis compared with biopsy. Among 190 patients with biopsy-proven hepatic steatosis, 69 were diagnosed with autoimmune hepatitis (AIH), 18 with primary biliary cholangitis (PBC), and 27 with AIH-PBC overlap syndrome. The AUROCs of CAP for the diagnosis of steatosis in AILDS were 0.878 (0.791-0.965) for S1, 0.764 (0.676-0.853) for S2, and 0.821 (0.716-0.926) for S3. The CAP value was significantly related to hepatic steatosis grade (P < 0.001). Among 69 patients with AIH, the median CAP score was 205.63 ± 47.36 dB/m for S0, 258.41 ± 42.83 dB/m for S1, 293.00 ± 37.18 dB/m for S2, and 313.60 ± 27.89 dB/m for S3. Compared with patients with nonalcoholic fatty liver disease (NAFLD) presenting with autoimmune markers, patients with AIH concomitant with NAFLD were much older and had higher serum IgG levels and LSM values. CAP can be used as a noninvasive diagnostic method to evaluate hepatic steatosis in patients with AILDs. Determination of LSM combined with CAP may help to identify patients with AIH concomitant with NAFLD from those with NAFLD with autoimmune phenomena.
登录
查看更多内容
影响因子：
25.7
作者：
Lohse, Ansgar W.;Chazouilleres, Olivier;Lenzi, Marco
通讯作者：
Lenzi, Marco
影响因子：
2.9
作者：
Sasso, Magali;Audiere, Stephane;Miette, Veronique
通讯作者：
Miette, Veronique
影响因子：
13.5
作者：
Chazouillères, O;Wendum, D;Poupon, R
通讯作者：
Poupon, R
DOI：
10.1111/liv.12809
发表时间：
2015-11
期刊：
Liver international : official journal of the International Association for the Study of the Liver
影响因子：
--
作者：
Shen F;Zheng RD;Shi JP;Mi YQ;Chen GF;Hu X;Liu YG;Wang XY;Pan Q;Chen GY;Chen JN;Xu L;Zhang RN;Xu LM;Fan JG
通讯作者：
Fan JG
影响因子：
25.7
作者：
Hirschfield, Gideon M.;Beuers, Ulrich;Marzioni, Marco
通讯作者：
Marzioni, Marco